Tyrosine kinase inhibitors have improved survival outcomes for patients with CML, but these agents also have a greater risk for adverse cardiovascular events.
A review of data from patients with CML treated with TKIs identified risk factors for developing pulmonary hypertension in these patients.
Researchers seek to characterize adherence trajectories, determine how side effects or financial status influence adherence, assess how adherence effects clinical outcomes, and explore unique patient perspectives.
Researchers sought to determine the risk of hepatotoxicity for patients with CML treated with 4 newer TKIs compared with imitanib.
A dose-reduction strategy in patients with CP-CML receiving dasatinib was shown to be feasible and may reduce adverse effects in these patients.